Hawyu

Hawyu is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to developing innovative small molecule drugs for metabolic and renal diseases. The company's primary focus is on addressing unmet medical needs in hyperuricemia and gout, conditions with significant global prevalence. Its lead product candidate, HY-001, is a highly selective URAT1 inhibitor currently in late-stage clinical trials, demonstrating promising efficacy in lowering serum uric acid levels with a favorable safety profile. Hawyu's pipeline also includes several other proprietary programs targeting various metabolic and inflammatory pathways. The company is backed by prominent venture capital firms and maintains a robust R&D facility to support its drug discovery efforts.